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Background: There is a paucity of data regarding clinical outcomes associated with the integration of a mild
therapeutic hypothermia (MTH) protocol into a regional network dedicated to treatment of patients with acute
coronary syndromes (ACS). Additionally, a recent report suggests that the neurological benefits of MTH therapy in
interventionally managed ACS patients resuscitated from out-of-hospital cardiac arrest (OHCA) may be potentially
offset by the catastrophic occurrence of stent thrombosis. The goal of this study was to share our experience with
the implementation of an MTH program using a previously established ACS network in consecutive comatose
OHCA survivors undergoing interventional management due to an initial diagnosis of ACS and to assess the clinical
effectiveness and safety of MTH.
Methods: We conducted a retrospective historically controlled single centre study. Hospital survival with a
favourable neurological outcome (Cerebral Performance Category of 1 or 2) and all-cause in-hospital mortality were
the primary and secondary efficacy end points, respectively. Occurrence of definite stent thrombosis was the
primary safety end point while the development of pneumonia, presence of positive blood cultures, occurrence of
probable stent thrombosis, any bleeding complications, need for red blood cell transfusion and presence of rhythm
and conductions disorders during hospitalisation constituted secondary safety end points.
Results: Comatose OHCA survivors (n = 32) were referred to our Department based on ECG recording transmissions and/
or phone consultations or admitted from the Emergency Department. Compared with controls (n = 33), they were
significantly more likely to be discharged from hospital with a favourable neurological outcome (59 vs. 27%; p < 0.05;
number needed to treat [NNT] = 3.11) and experienced lower all-cause in-hospital mortality (13 vs. 55%; p < 0.05; NNT =
2.38). Rates of all safety end points were similar in patients treated with and without MTH.
Conclusions: Our study indicates that a regional system of care for OHCA survivors may be successfully implemented
based on an ACS network, leading to an improvement in neurological status and to a reduction of in-hospital mortality in
patients treated with MTH, without any excess of complications. However, our findings should be verified in large,
prospective trials.
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Cardiac arrest constitutes the most frequent reason for
sudden death in developed countries. It is estimated that
each year 275,000 and 235,000 to 325,000 new cases of
out-of-hospital cardiac arrest (OHCA) occur in Europe
and the United States, respectively [1,2]. The rate of ad-
mission to hospital after a successful return of spontan-
eous circulation in adult OHCA patients is estimated
to be around 15% [3]. Although the survival of adult
OHCA victims admitted to hospital has increased re-
cently, approximately 60% of these patients still die be-
fore hospital discharge [4]. Furthermore, only two thirds
of OHCA survivors are discharged from hospital in a
good neurological condition [5].
Mild therapeutic hypothermia (MTH) remains one of
few interventions proven to improve clinical outcomes in
the setting of OHCA [6,7]. Based on evidence from ran-
domized clinical trials [6-9], the Advanced Life Support
Task Force of the International Liaison Committee on Re-
suscitation in 2003 [10] and subsequently The European
Resuscitation Council in 2005 [11] recommended MTH in
unconscious adult patients with recovery of spontaneous
circulation after OHCA when the initial rhythm was ven-
tricular fibrillation. Additionally, according to these rec-
ommendations MTH may also be beneficial for other
rhythms or in-hospital cardiac arrest [10,11]. Finally, the
role of MTH was appreciated by the European Society of
Cardiology in 2012 [12]. The guidelines for the manage-
ment of acute myocardial infarction in patients presenting
with ST-segment elevation indicate implementation of
MTH “early after resuscitation of cardiac arrest patients
who are comatose or in deep sedation” (class of recom-
mendation I, level of evidence B).
On the contrary, some international experts express
the opinion that MTH due to the substantial risk of bias
in randomized clinical trials and their overall small size
and low quality should be further evaluated [13,14].
Additionally, even though a recent meta-analysis of
randomized clinical trials conducted by the Cochrane
Collaboration demonstrated impressive efficacy of MTH
(the number needed to treat [NNT] of 6 for discharge in
a good neurological condition; NNT of 7 for survival to
hospital discharge) [15], this therapeutic method is still
underutilized in many European countries including
Poland [16,17]. This fact stands in apparent contrast to
the high penetration of interventional treatment in the
setting of acute coronary syndromes (ACS) and the pres-
ence of well-developed ACS networks in these countries
[18]. Of major importance, vast majority of patients
from landmark randomized clinical trials on MTH were
treated conservatively, despite the dominating presumed
cardiac origin of OHCA [6,7]. There is a paucity of data
regarding clinical outcomes associated with the integra-
tion of MTH protocols into regional networks dedicatedto treatment of ACS patients. A recent observational
American report suggests that such management leads to
a favourable prognosis in a substantial proportion of co-
matose OHCA patients [19]. On the other hand, the
neurological benefits of MTH therapy in interventionally
managed ACS patients may be potentially offset by the
catastrophic occurrence of stent thrombosis as suggested
by the just published case series from Barcelona [20].
The goal of this study is to share our experience regard-
ing the implementation of an MTH program using a pre-
viously established ACS network in comatose OHCA
survivors undergoing interventional management due to
an initial diagnosis of ACS and to assess the clinical effect-
iveness and safety of MTH.
Methods
Study design
We conducted a retrospective historically controlled
single centre study. Consecutive adult comatose OHCA
survivors with an initial diagnosis of ACS who received
MTH therapy between 2010 and 2011 were compared
with their consecutive counterparts fulfilling all criteria
for therapy with MTH, but not treated with this method,
as they were hospitalized before implementation of the
MTH program, namely in 2008 and 2009.
Qualification criteria for MTH included: unconsciousness
with no verbal contact, Glasgow Coma Score below 9
points, age of at least 18 years, and eligibility for mechanical
ventilation. Exclusion criteria for MTH were as follows:
Glasgow Coma Score equal or above 9 points, maintained
verbal contact, vegetative state or severe brain damage be-
fore OHCA, history of severe infection prior to OHCA, all
prior conditions with estimated length of survival below
one year, active bleeding unresponsive to treatment, active
intracranial bleeding, bleeding diathesis unless induced with
drugs, pregnancy (ruled out in all women below 50 years of
age with a pregnancy test; however, after the update of the
European Resuscitation Council guidelines in December
2010 [21] early gestation was no longer regarded as a
contraindication for MTH), hemodynamic instability de-
fined as systolic arterial pressure below 65 mm Hg despite
therapy with vasopressors and/or application of intraaortic
balloon counterpulsation (IABP) with reassessment after
hemodynamic stabilization, electrical instability defined as
the need for defibrillation or cardioversion within 30 minutes
preceeding qualification for MTH (with reassessment
once patient electrically stable), and symptomatic brad-
yarrhythmias unresponsive to endocardial pacing.
Study conduction and MTH procedure
OHCA survivors were referred to our Department simi-
larly to other ACS patients either based on a telephone
consultation predominantly accompanied by an ECG
transmission through the LIFENET System (Medtronic,
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or admitted directly from the Emergency Department of
our hospital.
Adult patients were qualified to therapy with MTH re-
gardless of the initial rhythm during OHCA, time to re-
turn of spontaneous circulation and age. The baseline
neurologic assessment was routinely performed twice
within the initial 30 minutes of the qualification proced-
ure, and optionally followed whenever feasible by further
neurologic evaluation only when necessitated by prior ad-
ministration of sedatives and their antidotes.
Patients with an initial diagnosis of ACS with ST-
segment elevation and/or in shock of clear cardiac origin
were transferred directly from the ambulance, rescue heli-
copter or Emergency Department to the cathlab to avoid
any delay in revascularization. The decision concerning
qualification to therapy with MTH was made immediately
after the patient’s admission. Subsequently, induction of
MTH was initiated with the infusion of cold normal saline
(0.9% solution of sodium chloride at the temperature of
4°C) and the usage of ice packs.
All patients from both the study and control group
underwent coronary angiography, followed, if clinically in-
dicated, by percutaneous coronary intervention (PCI).
Coronarography and PCI were performed using a stand-
ard femoral approach. Intracoronary stents were routinely
implanted. Complete revascularization was intended in all
patients with cardiogenic shock. Optimal direct effect of
the intervention was assigned when no residual stenosis
or a stenosis of less than 20% of the reference segment
diameter along with TIMI (Thrombolysis in Myocardial
Infarction) 3 flow in the PCI-treated artery were observed.
Suboptimal direct effect of PCI was defined as the pres-
ence of a residual stenosis between 20 and 50% of the
reference segment diameter and/or TIMI 2 flow the
PCI-treated artery. A residual stenosis exceeding 50% of
the reference segment diameter and/or TIMI 0 or 1 flow
were considered ineffective effects of PCI. The use of as-
piration thrombectomy during the intervention was left to
the operator’s discretion.
Transthoracic echocardiography was performed in all
study participants on the day of admission and thereafter
whenever needed and serial ECG recordings were taken at
baseline, after coronary angioplasty and/or coronary angi-
ography and thereafter when clinically indicated. In case
of any doubts regarding the reason of OHCA, additional
diagnostic procedures including head and/or chest com-
puted tomography were performed before the initiation of
the MTH procedure.
An MTH-dedicated catheter was placed by the interven-
tional cardiologist in the cathlab in the inferior vena cava
through the femoral vein. The cooling system applied in
our study was CoolGard 3000 (Alsius, Zoll, Chelmsdorf,
MA, USA) allowing for precise and rapid control of thepatient’s core temperature for both cooling and warming.
The cooling procedure with the CoolGard 3000 system
was started immediately after the patients had been trans-
ferred from the cathlab to Cardiac Intensive Care Sub-unit.
The state of MTH was defined as the patient’s core
temperature below 34°C, with a target temperature of
33°C. MTH was maintained for at least 12, with the opti-
mal duration of MTH of 24 hours. The rewarming phase
was actively controlled and performed at a rate of 0.3°C
per hour. Two independent measurements of the patient’s
core temperature were continuously taken in the urinary
bladder and in the lower one third of the oesophagus using
a dedicated catheter and tube, respectively.
All study participants were hospitalized in a 5-bed Car-
diac Intensive Care Sub-unit that remains an integral part
of the 24-bed Coronary Care Unit in our department.
Medical care was delivered by cardiologists experienced in
acute cardiac care and supported when needed by a multi-
disciplinary team of specialists available in an academic
hospital, including anaesthesiologists, clinical microbiolo-
gists, clinical nutritionists, endoscopic gastroenterologists,
general and vascular surgeons, medical rehabilitation spe-
cialists, nephrologists, neurologists and otolaryngologists.
All patients were mechanically ventilated and given con-
tinuous intravenous infusion of propofol and fentanyl for
sedation and analgesia, respectively. Standard management
of shivers included a combination of superficial rewarming,
buspirone and magnesium, and was supplemented by
atracurium when the shivers were resistant to the first-line
therapy. All drugs were administered in a weight-adjusted
manner.
All patients underwent continuous monitoring of inva-
sive blood pressure, central venous pressure, ECG and
hourly diuresis as well as multiple laboratory blood tests
were performed according to our local MTH protocol
(details available on request).
We aimed to achieve and maintain the hemodynamic
and laboratory targets recommended by the International
Liaison Committee for patients with post-cardiac arrest
syndrome [22] such as mean arterial pressure of 65–100 -
mmHg (depending on the patient’s normal blood pressure,
the cause of OHCA, and the severity of myocardial
dysfunction), central venous pressure of 8–12 mmHg,
central venous oxygen saturation above 70%, urine
output >1 mL × kg-1 × h-1 and a normal or decreasing
serum or blood lactate level.
The study protocol was approved by the Local Bioethics
Committee at Collegium Medicum of the Nicolaus Coper-
nicus University in Torun in accordance with the
Declaration of Helsinki.
Concomitant therapy
At the first contact with health care providers all study
participants with a confirmed diagnosis of ACS were
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heparin (70 IU/kg, up to 5000 IU) and oral loading doses
of clopidogrel (600 mg) and aspirin (300 mg) administered
as crushed tablets via nasogastric tube. In patients with an
uncertain initial diagnosis loading with unfractionated
heparin and antiplatelet agents was deferred until ACS
confirmation. At the catheterization laboratory, patients
undergoing PCI received second dose of unfractionated
heparin intraarterially in a weight-adjusted manner (up to
100 IU/kg) or under activated clotting time guidance (to
the target range of 200–250 seconds) when abciximab was
intended. Therapy with unfractionated heparin under the
activated partial thromboplastin time monitoring (with a
therapeutic range of 1.5 to 2.5 times the control value)
was continued in all study participants until the end of
the rewarming phase. Then the patients were treated
with prophylactic doses of enoxaparin until their full
mobilization. Throughout the whole hospitalization as-
pirin was given to all patients with coronary artery disease
at a dose of 75 mg q.d. Continuation of clopidogrel ther-
apy was restricted to patients with a confirmed ACS diag-
nosis. Clopidogrel was administered at a dose of 150 mg q.
d. until the end of the rewarming phase in MTH-treated
patients and thereafter the dose was reduced to 75 mg q.d.
while the controls received clopidogrel maintenance doses
of 75 mg q.d. since the 2nd day until hospital discharge.
Dual antiplatelet therapy was recommended for 12 months,
unless the patient was considered to have a high risk of
bleeding, with the minimal duration of 1 and 12 months
after bare metal stent and drug-eluting stent implantation,
respectively. Abciximab was given at the discretion of
the invasive cardiologist. The drug was injected as an
intracoronary bolus of 0.25 mg/kg with a subsequent intra-
venous infusion of 0.125 mg/min over 12 h according to
the manufacturer’s recommendations.
If clinically indicated, norepinephrine was used as the
vasopressor-of-choice to restore blood pressure and main-
tain adequate tissue perfusion. All study participants with a
confirmed diagnosis of ACS received statin. Angiotensin-
converting-enzyme inhibitors and beta-blockers were initi-
ated in all patients on condition of sufficient values of blood
pressure. Loop diuretics were started in case of congestion
while aldosterone antagonists were given in patients with
left ventricular ejection fraction below 35% and concomi-
tant symptoms of heart failure or diabetes. All study partici-
pants received pantoprazole to prevent gastrointestinal
bleedings. The combination of amoxicillin and clavulanic
acid in doses adjusted to renal function was initiated imme-
diately after admission in all subjects from the MTH group
but not in patients from the control group. Therapy with
antibiotics was modified or started (in the control group) in
case of infection diagnosed based on the results of bron-
chial alveolar lavage, blood and urine cultures, inflamma-
tory markers and/or clinical judgement.All study participants received enteral nutrition in
order to provide energy and nutrient intake as well as to
preserve the gastrointestinal architecture and prevent
bacterial translocation from the colon.Study endpoints
Hospital survival with a favourable neurological outcome
and all-cause in-hospital mortality constituted the primary
and the secondary efficacy end point, respectively. To
evaluate the neurological status of the study participants
at hospital discharge, we applied the Pittsburgh Cerebral
Performance Category Scale [23] that remains a wide-
spread and validated tool for the neurological assessment
of patients treated with MTH [6,7,16]. It contains 5 cat-
egories: CPC-1 (good recovery), CPC-2 (moderate disabil-
ity), CPC-3 (severe disability), CPC-4 (vegetative status)
and CPC-5 (death). Survival with a favourable neurological
outcome was defined as a Pittsburgh Cerebral Perform-
ance Category of 1 or 2, implicating that patients falling in
these categories have sufficiently preserved brain function
to live independently [6,7,23].
Occurrence of definite stent thrombosis was the primary
safety end point while the development of pneumonia,
presence of positive blood cultures, occurrence of prob-
able stent thrombosis, any bleeding complications, need
for red blood cell transfusion and presence of rhythm and
conductions disorders during hospitalisation constituted
the secondary safety end points. Definite stent thrombosis
was defined as thrombosis within the stent confirmed an-
giographically or at autopsy. In the search of cases with
probable stent thrombosis in patients with unexplained
in-hospital death, we carefully analyzed all deaths of the
study participants.Statistical analysis and sample size calculation
Based on the data obtained by Knafelj et al. [24] in a simi-
lar population of OHCA survivors, we assumed the occur-
rence of the primary study end point (i.e. hospital survival
with a favourable neurological outcome with CPC-1 and
CPC-2), in 55% and 16% of patients treated with and with-
out MTH, respectively. With these assumptions it was cal-
culated before the enrolment of both control and MTH
group patients that it takes at least 30 patients per group
to demonstrate the significance of the difference in the oc-
currence of the primary study end point between patients
treated with and without MTH, allowing for 90.5% power
with a 2-sided alpha value of 0.05. To compensate for po-
tential loss of study participants due to various reasons,
we enrolled 5 additional patients.
The Shapiro-Wilk test was applied to verify normal dis-
tribution of the investigated continuous variables. Continu-
ous variables were presented as mean values ± standard
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pending on the presence or absence of normal distribution.
Therefore inter-group comparisons were performed with
Student’s t test for independent samples or the Mann–
Whitney unpaired rank sum test when appropriate. Cat-
egorical variables were expressed as the number of patients
presenting the given feature and the percentage of patients
in the analysed group. Categorical variables were compared
using the χ2 test with the Yates’ correction if required.
Univariate and multivariate logistic regression models
were used to identify predictors of efficacy end points. Var-
iables with a p-value of ≤0.1 in the univariate analysis were
introduced into the multivariate logistic regression model.
Subsequently, variables with no significant impact on
the prevalence of efficacy end points (p ≥ 0.05) were one by
one removed from the multivariate model according to
their decreasing p-values. Relations between investigated
variables and the likelihood of efficacy end points were es-
timated with the use of odds ratios (OR) with 95% confi-
dence intervals (95% CI). Optimal cut-off points were
determined using the receiver operator characteristic
(ROC) analysis. Additionally, for end points for which the
difference in their occurrence between patients treated
with and without MTH reached statistical significance, we
calculated the NNTand its 95% CI.
Two-sided differences were considered significant at
p < 0.05. The statistical analysis and sample size calcula-
tion were carried out using the Statistica 10.0 package
(StatSoft, Tulsa, OK, USA), while MedCalc 12.0 (MedCalc
Software, Mariakerke, Belgium) statistical software was
used for the ROC analysis.Results
MTH procedure and patient characteristics
The MTH group comprised of 32 patients who accounted
for 0.8% of the total of 4006 subjects hospitalized in our
department in 2010 and 2011 due to ACS. MTH was suc-
cessfully applied in all patients. The median time needed
to achieve the state of MTH counted from the initiation of
cooling with the infusion of cold saline and the usage of
ice packs was 400 minutes, with the interquartile differ-
ence ranging between 295.0 and 666.5 minutes. None of
the study participants was being cooled before hospital
admission. MTH procedure was continued for a median
of 24.0 (24.0-24.5) hours. Atracurium was administered in
9 (28.1%) patients due to shivers resistant to the first-line
therapy.
Both groups of patients were comparable in terms of
their demographic and clinical characteristics (Table 1). Al-
though patients receiving MTH were slightly older and less
frequently had a history of myocardial infarction, while
those treated conservatively presented with higher scores in
Glasgow Coma Scale and required shorter resuscitation torestore spontaneous circulation, all differences, except for
the lower proportion of patients with the final diagnosis of
ACS in the MTH group, were statistically nonsignificant.
Slightly fewer patients in the MTH group underwent PCI
than in the control group. Although patients in the latter
group presented with more complex angiographic and pro-
cedural characteristics (more patients treated with PCI of
left main coronary artery and left anterior descending
artery or multi-vessel PCI, higher prevalence of type C
lesions according to the American College of Cardiology/
American Heart Association classification treated with
PCI, worse baseline flow in the culprit artery, lower me-
dian diameter of implanted stents), all differences between
both groups were statistically nonsignificant (Table 2).
Abciximab was administered during PCI in similar pro-
portions of patients in both groups. The rate of IABP use,
although higher among the controls, showed no statisti-
cally significant difference as compared with patients re-
ceiving MTH.
In comparison with historical control groups, we found
a significant prolongation of hospitalization in patients
treated with MTH (18.5 [12.5-54.0] vs. 8.0 [3.0-14.5] days;
p < 0.00004). However, after exclusion of cases of in-
hospital death, the difference no longer remained signifi-
cant (19.0 [12.5-59.5] vs. 12.0 [10.0-22.0] days; p = ns).
Therefore it seems that this difference was driven by both
early deaths among patients from the control group and
application of MTH procedure.Impact of MTH on favourable neurological outcome
A total of 28 study participants were discharged from hos-
pital with a favourable neurological outcome. Therapy with
MTH was associated with a significantly higher number of
patients presenting a favourable neurological outcome both
in the overall study population as well as in the sub-group
of patients with shockable rhythms, but not in those with
non-shockable rhythms (Figure 1). However, we did not
find any difference in the proportions of patients discharged
in CPC category 1 or 2 and all patients who survived until
hospital discharge between subjects treated with MTH and
controls in the overall study population (19/28 [67.9%] vs.
9/15 [60.0%]; p = ns) nor in the sub-groups with shockable
(18/24 [75.0%] vs. 8/12 [66.7%]; p = ns) and non-shockable
rhythms (1/4 [25.0%] vs. 1/3 [33.3%; p = ns]). Detailed dis-
tribution of the cerebral performance categories according
to the CPC classification in patients undergoing MTH and
controls is displayed in Figure 2. Values of NNT for the
achievement of a favourable neurological outcome for the
overall study population and for the sub-group of patients
with ventricular fibrillation or pulseless ventricular tachy-
cardia were 3.11 (95% CI 1.82-10.73) and 2.90 (95% CI
1.65-12.25), respectively. A direct comparison of character-
istics of patients with and without in-hospital favourable
Table 1 Demographic and clinical characteristics of patients treated with and without mild therapeutic hypothermia
Variable Patients undergoing MTH procedure Control group p
(n = 32) (n = 33)
Demographic characteristics
Age [years] 65.6 ± 19.0 62.7 ± 9.8 ns
Gender: men/women 25 (78.1%)/7 (21.9%) 26 (78.8%)/7 (21.2%) ns
Medical history
Concomitant diabetes 13 (40.6%) 13 (39.4%) ns
Prior stroke 4 (12.5%) 3 (9.1%) ns
Prior myocardial infarction 8 (25.0%) 13 (39.4%) ns
Details regarding OHCA
First-recorded cardiac rhythm ns
Ventricular fibrillation or pulseless ventricular tachycardia 26 (81.3%) 26 (78.8%)
Asystole 5 (15.6%) 6 (18.2%)
Pulseless electrical activity 1 (3.1%) 1 (3.0%)
Initiation of cardiopulmonary resuscitation by bystanders 12 (37.5%) 10 (30.3%) ns
Time between OHCA and ROSC [minutes] 30.0 (25.0-56.0) 23.0 (18.0-37.0) ns
Duration of cardiopulmonary resuscitation [minutes] 25.0 (15.0-51.0) 20.0 (11.0-45.0) ns
Patient status on admission and in-hospital management
Glasgow Coma Score on hospital admission ns
3-4 points 22 (68.8%) 18 (54.6%)
5-6 points 7 (21.9%) 11 (33.3%)
7-8 points 3 (9.3%) 4 (12.1%)
Arterial pH on hospital admission 7.26 (7.20-7.33) 7.30 (7.16-7.36) ns
Shock on hospital admission 15 (46.9%) 14 (42.4%) ns
LVEF on hospital admission [%] 35.0 (30.0-45.0) 30.0 (25.0-40.0) ns
Underlying cause of OHCA p < 0.04
STEMI 24 (75.0%) 22 (66.7%)
NST-ACS 2 (6.2%) 9 (27.3%)
Other 6 (18.8%) 2 (6.0%)
Presence of coronary artery disease ns
single-vessel 7 (21.9%) 11 (33.3%)
multi-vessel 17 (53.1%) 20 (60.6%)
lack of significant coronary lesions 8 (25.0%) 2 (6.1%)
Treatment with PCI 24 (75.0%) 27 (81.8%) ns
Use of intra-aortic balloon counterpulsation 4 (12.5%) 9 (27.3%) ns
LVEF Left ventricular ejection fraction; MTH Mild therapeutic hypothermia; NST-ACS Non-ST-segment elevation acute coronary syndrome; OHCA Out-of-hospital
cardiac arrest; PCI Percutaneous coronary intervention; ROSC Successful return of spontaneous circulation; STEMI ST-segment elevation myocardial infarction.
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revealed significant differences concerning patients’ age
(54.4 ± 11.5 vs. 66.2 ± 9.6 years; p < 0.00004); the duration
of cardiopulmonary resuscitation (18.5 [9.0-30.0] vs. 25.0
[20.0-57.0] minutes; p < 0.04), proportion of patients with
Glasgow Coma Score > 3 points on hospital admission (21/
28 [75.0%] vs. 17/37 [45.9%]; p < 0.02) and the proportion
of patients treated with MTH (19 [67.9%] vs. 13 [35.1];
p < 0.01). Additionally, logistic regression analysis (both uni-
variate and multivariate) indicated a significant prognosticvalue of MTH therapy in terms of predicting a favourable
neurological outcome (Table 3). Logistic regression-based
calculations also identified younger age as a powerful pre-
dictor of in-hospital survival with a favourable neurological
outcome with the highest diagnostic accuracy at the cut-off
value of ≤56.0 years of age as calculated in the ROC curve
analysis (sensitivity 57.1%, specificity 86.5%, positive pre-
dictive value 76.2%, negative predictive value 72.7%). The
area under the ROC curve for patients’ age was 0.69
(95% CI 0.63- 0.76).
Table 2 Angiographic and procedural characteristics of
the study participants undergoing percutaneous








(n = 24) (n = 27)






Number of coronary arteries
treated with PCI
ns
single-vessel PCI 17 18
dual-vessel PCI 6 9
triple-vessel PCI 1 2
Number of lesions treated with PCI ns
single-lesion PCI 13 14
dual-lesion PCI 9 12
triple-lesion PCI 2 1
Type of lesion treated with PCI






Baseline flow in the culprit artery ns
TIMI 0 or 1 15 20
TIMI 2 1 1
TIMI 3 8 7
Final flow in the culprit artery ns
TIMI 0 0 1
TIMI 3 24 26
Number of stents implanted
for patient
ns
0 0 2 #
1 10 12
2 8 8
3 or more 5 5
Type of implanted stent ns
bare metal stent 42 48
drug-eluting stent 1 0
Total length of implanted stents
per patient [mm]
33 (15–44) 33 (16–50) ns
Diameter of implanted stent [mm] 3.3 (2.8-3.5) 3.0 (2.8-3.4) ns
Therapy with abciximab 5 (20.8%) 5 (18.5%) ns
Table 2 Angiographic and procedural characteristics of
the study participants undergoing percutaneous
coronary intervention in relation to the treatment with
mild therapeutic hypothermia (Continued)
Application of thrombectomy 6/24 3/27 ns
Door-to-balloon time * [minutes] 40.5 (31.5-68.5) 70.0 (32.0-
81.0)
ns
Direct effect of PCI





# One patient underwent exclusively plain old balloon angioblasty while
another one had an unsuccessful attempt of PCI. * In case of multi-vessel PCI
door-to-balloon time refers to the culprit lesion. ACC American College of
Cardiology; AL Intermediate artery; AHA American Heart Association; Cx
Circumflex artery; LAD Left anterior descending artery; LM Left main coronary
artery; MTH Mild therapeutic hypothermia; PCI Percutaneous coronary
intervention; RCA Right coronary artery.
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A total of 22 study participants died during the index
hospitalization. As shown in Figure 3, patients undergoing
MTH when compared with the control group experienced
remarkably lower all-cause in-hospital mortality (NNT =
2.38; 95% CI 1.60-4.67). The difference was even more
pronounced in those with shockable rhythms (NNT =
2.21; 95% CI 1.47-4.53). A direct comparison of character-
istics of cases of in-hospital deaths and survivals including
all variables listed in Table 1 revealed significant differen-
ces regarding patients’ age (66.2 ± 8.6 vs. 58.4 ± 12.6 years;
p < 0.02); proportion of patients with Glasgow Coma
Score > 3 points on hospital admission (8/22 [36.4%]
vs. 30/43 [69.8%] points; p < 0.01) and the propor-
tion of OHCA patients treated with MTH (4 [18.2%] vs.
28 [65.1%]; p = 0.0009). Furthermore, both univariate and
multivariate analyses identified the lack of MTH therapy
as a significant predictor of all-cause in-hospital mortality
(Table 4). In addition to the previous, elderly age was also
independently associated with the risk of in-hospital
death, with the area under the curve of 0.67 as revealed by
a ROC curve analysis to assess the diagnostic accuracy for
the prediction of all-cause in-hospital mortality (95% con-
fidence interval 0.54-0.78; p < 0.01). The corresponding
optimal cut-off value was >56.0 years of age (sensitivity
90.9%, specificity 44.2%, positive predictive value 45.5%,
negative predictive value 90.5%).
Safety of MTH therapy
Neither definite nor probable stent thrombosis occurred in
MTH-treated patients. Similarly, none of the patients from
the control group developed definite stent thrombosis,
while 2 patients from this group were classified as having
probable stent thrombosis. These patients died suddenly on
the 2nd and 4th day of hospitalization, respectively, despite
Figure 1 Comparison of hospital survival with a favourable neurological outcome in patients treated with and without mild
therapeutic hypothermia. The results are reported as the percentage and the number of patients with a favourable neurological outcome of
patients in the analysed group. MTH - mild therapeutic hypothermia.
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planation for their deaths. Unfortunately, in both cases aut-
opsy was not performed. Despite high absolute rates of
pneumonia, we found no difference in respect to the pri-
mary safety end point between patients treated with and
without MTH (Table 5). We also noted similar proportions
of subjects with positive blood cultures in both groups.
Similarly, the rates of bleeding complications as well as
rhythm and conduction disorders did not differ between
patients undergoing MTH and controls. However, the inci-
dence of bleedings of any severity and red blood cell
transfusions was numerically higher in patients treated
with MTH. Cardioverter-defibrillators were implanted dur-
ing the index hospitalization in 7 patients (21.9%) in the
MTH group and in only 1 patient (3.0%) in the control
group (p = 0.053). None of the study participants
underwent pacemaker implantation during the index
hospitalization.
Discussion
According to our best knowledge this study is the first
European report proving that implementation of an
MTH program for the treatment of comatose OHCA
survivors based on a previously established ACS network
improves clinical outcomes. Additionally, our data indi-
cate that a standardized MTH protocol may be success-
fully developed and used by cardiologists trained in
acute cardiac care. Our study together with the first
overall experience from the Minneapolis Heart Institute
[19] strongly supports the concept of implementation of
MTH programs in centres which provide interventionaltreatment for ACS patients. The clinical effectiveness of
MTH, namely the enormous improvement in neurological
status and striking reduction in all-cause in-hospital mor-
tality among patients treated with this method when com-
pared with a historical control group, was even greater in
our study than in randomized clinical trials [6-9]. Of major
importance, according to our data, treatment with MTH
was not accompanied by any excess of complications in-
cluding stent thrombosis, bleedings and infections as well
as rhythm and conductions disorders.
Organization of regional systems of care for comatose
OHCA survivors is robustly encouraged by international
experts [13,25,26]. In support of the recommendation on
the development of regional systems of care for OHCA pa-
tients, an analysis of a Japanese registry including 10,383
patients demonstrated that the rate of neurologically
favourable 1-month survival after OHCA of presumed car-
diac aetiology in patients transported to critical cardiac
care hospital was higher than in those transported to hos-
pitals without specialized cardiac facilities (6.7 vs. 2.8%;
p < 0.001) [27]. In line with this observation, a recent pro-
spective cohort study of the Resuscitation Outcomes Con-
sortium (ROC) suggested better survival to discharge if
closer, but inadequately equipped hospitals were bypassed
in favour of further hospitals with more advanced thera-
peutic capabilities (16.5 vs. 12.1%) [28]. Furthermore, the
ROC investigators noted higher survival rates to discharge
in hospitals performing cardiac catheterization (34 vs. 27%;
p = 0.001) and in hospitals with at least 40 OHCA patients
per year (37 vs. 30%; p = 0.01) [29]. Finally, Mooney et al.,
who for the first time superimposed an MTH program for
Figure 2 Distribution of categories according to the Pittsburgh Cerebral Performance Category Scale in the patients undergoing mild
therapeutic hypothermia and in the control group. CPC- Cerebral Performance Category; MTH - mild therapeutic hypothermia.
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all survival to hospital discharge rate of 56% among 140
study participants, with 92% of survivors discharged in the
CPC category of 1 or 2 [20]. Three quarters of the patients
(n = 107) in this study were transferred to the MTH-
capable hospital from referring network hospitals. Whether
transferred or not to the MTH-capable centre, the patients
showed similar survival rates. Although both, our study
and the original one, refer to the same clinical scenario,
they differ in several aspects. Not only is our series much
smaller than the report from Minneapolis Heart Institute,
but it also indicates a lower rate of bystander cardiopulmo-
nary resuscitation (38 vs. 66%), longer time from cardiac
arrest to the return of spontaneous circulation (30 vs.
22 minutes), and higher overall survival rate at hospital dis-
charge (87 vs. 56%). Surprisingly, we noted a higher pro-
portion of patients surviving with significant neurologic
impairment in the MTH group (32.1%) than in mostTable 3 Predictors of hospital survival with a favourable neur
Univariate
OHCA with shockable rhythm
Treatment with MTH
Glasgow Coma Score on hospital admission [patients with >3 points vs. patie
Prior myocardial infarction
Age [for a 10 year increase]
Multivariate
Treatment with MTH
Age [for a 10 year increase]
Results are presented according to decreasing values of odds ratios.
CI Confidence interval; MTH Mild therapeutic hypothermia; OHCA Out-of-hospital careports including the study conducted by Mooney et al.
[6-9,20]. However, this potentially alarming finding should
be interpreted with caution due to the limited sample size
of our study and the true occurrence of poor neurologic
outcome among OHCA survivors treated with MTH
should be carefully evaluated in large multicentre registries.
Our ACS network was developed in 2002 in order to
provide optimal care for ACS patients in the Kuyavia and
Pomerania Region, particularly aiming to identify high-
risk ACS subjects to enable their immediate transportation
to experienced PCI centres. The implementation of a
standarized MTH program in 2010, complements the rest
of modalities employed so far in the care of OHCA survi-
vors, such as mechanical ventilation, circulatory support
with IABP and invasive and non-invasive techniques of
haemodynamic status monitoring. Based on this evidence
supporting the beneficial impact of MTH in post-OHCA
patients, we find it reasonable to further encourage healthological outcome in univariate and multivariate analysis
analysis
OR 95% CI p
5.50 1.07-28.16 p < 0.05
3.90 1.35-11.27 p < 0.02
nts with 3 points] 3.53 1.18-10.53 p < 0.02
0.38 0.12-1.20 p = 0.097
0.34 0.18-0.63 p < 0.001
analysis
OR 95% CI p
4.13 1.20-14.19 p < 0.03
0.33 0.17-0.64 p < 0.002
rdiac arrest; OR Odds ratio.
Figure 3 Comparison of all-cause in-hospital mortality in patients treated with and without mild therapeutic hypothermia. The results
are reported as the percentage and the number of patients who died during the index hospitalization in the analysed group. MTH - mild
therapeutic hypothermia.
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tion in our system of care for OHCA survivors. Patients
treated with MTH in our study accounted for merely 0.8%
of all ACS patients hospitalized in our department in 2010
and 2011 and it is likely that even currently a large num-
ber of OHCA patients are still being admitted to general
intensive care units without MTH facilities.
In our opinion, the following factors, absent or under-
utilized in randomized clinical trials, including administra-
tion of cold intravenous infusions preceding endovascular
cooling, routine performance of coronary angiography
combined, if needed, with PCI in all OHCA survivors with
the initial ACS diagnosis, multidisciplinary specialist care
and use of continuous monitoring of invasive bloodTable 4 Predictors of all-cause in-hospital mortality in univari
Univariate
Age [for a 10 year increase]
LVEF on admission [for a 10% increase]
Glasgow Coma Score on hospital admission [patients with >3 points vs. patie
Treatment with MTH
Multivariate
Age [for a 10 year increase]
Treatment with MTH
CI Confidence interval; LVEF Left ventricular ejection fraction; MTH Mild therapeutic
Results are presented according to decreasing values of odds ratios.pressure and central venous pressure might potentially
contribute to the extent of clinical benefits observed in
our MTH group. Although the MTH and control groups
in our study were similar in terms of their characteristics,
it is likely that some of these factors may exert a synergis-
tic effect to that attributed to the treatment with MTH.
In contrast to the latest recommendation of the
European Resuscitation Council Guidelines to use MTH
in comatose OHCA survivors with initially non-shockable
rhythms [29], we failed to prove any benefits of MTH in
this particular population. Although our study was under-
powered to assess clinical outcomes in this sub-group, our
results correspond with those obtained in numerous
[30-32], but not all [8,33,34], previous observational andate and multivariate analysis
analysis
OR 95% CI p
1.88 1.11-3.18 p < 0.02
0.56 0.30-1.06 p = 0.074
nts with 3 points] 0.25 0.08-0.73 p < 0.02
0.12 0.03-0.43 p < 0.002
analysis
OR 95% CI p
2.09 1.10-3.96 p < 0.03
0.11 0.03-0.43 p < 0.003
hypothermia; OR Odds ratio.
Table 5 Comparison of the occurrence of safety end







(n = 32) (n = 33)
Definite stent thrombosis* 0 (0%) 0 (0%) ns
Probable stent thrombosis* 0 (0%) 2 (7.4%) ns
Pneumonia 19 (59.4%) 19
(57.6%)
ns
Positive blood culture 12 (37.5%) 11
(33.3%)
ns
Bleeding of any severity 8 (25.0%) 5
(15.2%)
ns




Atrial fibrillation 6 (18.8%) 7
(21.2%)
Ventricular tachycardia 3 (9.4%) 1 (3.0%) ns
Clinically relevant
bradycardia
3 (9.4%) 1 (3.0%) ns
* The percentage refers to the number of patients treated with percutaneous
coronary intervention in the group. MTH Mild therapeutic hypothermia.
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sive evidence, the guidelines acknowledge a lower level of
evidence for the use of MTH after cardiac arrest from
non-shockable rhythms than from shockable ones [12].
OHCA patients with non-shockable rhythms have much
poorer outcomes than their counterparts with shockable
rhythms, particularly due to more comorbidities and fre-
quently longer periods from the OHCA occurrence to the
initiation of resuscitation [4]. Therefore it is likely that
MTH may be insufficient to reverse the unfavourable prog-
nosis in a substantial proportion of OHCA victims with
non-shockable rhythms. To clarify the efficacy of MTH
in patients with non-shockable rhythms, an adequately
designed randomized trial in this population is warranted.
The presence of coronary artery disease in up to 71% of
OHCA victims together with acute coronary artery
occlusion in nearly a half of them provides a solid ration-
ale for the performance of coronary angiography in these
patients [35]. These numbers reported by Spaulding et al.
correspond with our data. Of interest, the absence of
ST-segment elevation on the surface 12-lead ECG after
cardiopulmonary resuscitation does not guarantee coron-
ary vessels patency. It is even estimated that approximately
20-30% of patients after OHCA present with coronary
artery occlusion or an unstable coronary lesion, despite
the lack of ST-segment elevation [36,37]. An analysis
of Arizona SHARE database indicates an underlying
noncardiac aetiology in only 20% of adult nontraumatic
OHCA cases [38]. Numerous recent reports demonstratesubstantial advantages of coronary revascularisation in
patients after OHCA [24,36,39,40]. For example, in the
PROCAT (Parisian Region Out of Hospital Cardiac
Arrest) registry successful PCI was demonstrated to be an
independent predictor of survival, regardless of the
postresuscitation ECG pattern (odds ratio 2.06; 95% confi-
dence interval 1.16-3.66) [36]. Therefore, we believe that
combining early coronary angiography and PCI with
timely induction of MTH should be considered an optimal
strategy in this setting. However, we need to facilitate pre-
selection of patients, particularly those without ST-
segment elevation, benefiting from PCI after OHCA to
avoid unnecessary coronary angiographies. Among 435
patients with a cardiac cause of OHCA included in the
above mentioned PROCAT registry, ST-segment elevation
was present in 134 subjects while the rest of participants
presented with other ECG patterns. Successful PCI was
completed in 74% and 26% of patients in the former and
in the latter group, respectively.
Of major importance, a recent case series including 11
patients treated with MTH and coronary stenting (13 bare-
metal stents and 3 drug-eluting stents) indicated an unex-
pectedly high rate of in-hospital stent thrombosis (45.5%),
despite the periprocedural administration of abciximab in 6
patients including 5 of 6 subjects with stent thrombosis
[20]. In 4 patients, stent thrombosis was diagnosed during
coronary angiography, and in the last one, the diagnosis
was made at autopsy. When compared with non-OHCA
patients undergoing coronary stenting due to ACS in
the routine clinical practice, the rate of stent thrombosis
reported by Penela et al. remains extremely high (1–3 vs.
45,5%) even considering the phenomena of MTH-related
increased ADP-induced platelet aggregation and impaired
bioavailability and antiplatelet effect of clopidogrel in
OHCA patients [20,41-43]. In contrast to this observation,
we found in our data no cases of stent thrombosis in
MTH-treated patients. It might be partially attributed to
doubling the clopidogrel maintenance dose and ongoing
therapy with unfractionated heparin in our study group but
the possible excess of stent thrombosis in the MTH settings
warrants further investigation.
As stated in the guidelines of European Society of Cardi-
ology for the management of acute myocardial infarction in
patients presenting with ST-segment elevation the optimal
sequence of cooling and PCI in OHCA survivors is unclear
[13]. Preclinical studies and small clinical trials suggested
that MTH if obtained before reperfusion may reduce infarct
size [44,45]. However, the hypothesis regarding clinical ben-
efits of MTH in non-OHCA patients with myocardial in-
farction warrants further investigation. This approach
requires dedicated local techniques such as transcoronary
induction of MTH using a catheter or wire lumen to limit
the cooling area to myocardium in conscious patients
undergoing primary PCI. Although the induction of MTH
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angiography, it is unlikely that the clinical benefits of MTH
in our study were related to the protective effect of cooling
on myocardium since the median time needed to achieve
the state of MTH was as long as 400 minutes.
Available evidence from animal models and small case
series of human patients suggest an advantageous effect of
MTH in the setting of post-myocardial infarction cardio-
genic shock [46,47]. German researchers, who compared
20 consecutive patients admitted in cardiogenic shock
after successful resuscitation from OHCA and treated
with MTH with 20 matched subjects from a historic nor-
mothermic control group, observed in the former a signifi-
cant decrease in heart rate and marked increase in
ejection fraction, mean arterial pressure and systemic vas-
cular resistance, with no change in cardiac index [47]. Ac-
cordingly, patients from the MTH group required lower
cumulative doses of vasopressors and inotropes. Other po-
tentially beneficial physiologic effects of MTH in cardio-
genic shock include lower oxygen consumption along
with protection from myocardial damage and reduction of
end-organ injury from prolonged hypoperfusion [46]. In
our study, cardiogenic shock on admission was present in
46.9 and 42.4% of patient treated with and without MTH,
respectively. Surprisingly, the presence of cardiogenic
shock on admission did not carry an adverse prognosis in
our study but it should be emphasized that all study
participants underwent invasive management and patients
with ongoing hemodynamic instability (systolic arterial
pressure below 65 mm Hg), despite therapy with vasopres-
sors and/or application of IABP, were not eligible for
MTH treatment unless they achieved hemodynamic
stabilization. On the other hand, we cannot exclude that
this observation may be attributed to the favourable im-
pact of MTH. However, the efficacy and safety of MTH in
patients with cardiogenic shock needs to be verified in ad-
equately designed randomized trials.
The HACA (the Hypothermia after Cardiac Arrest
Study) investigators found a numerically higher, but sta-
tistically insignificant, prevalence of pneumonia in the
MTH group than in the normothermia group [6]. It
raised concerns regarding the safety of the method. A
meta-analysis conducted by Arrich et al. did not confirm
the detrimental effect of MTH on the occurrence of
pneumonia and other adverse events [16]. These find-
ings are in line with our results. However, all trials in-
cluded in this meta-analysis, similarly to our study, were
underpowered to show modest differences in the preva-
lence of safety end points. On the other hand, pneumonia
occurred in almost 60% of our study participants which is
comparable with other studies [48,49]. Therefore, pneu-
monia, usually caused by aspiration or mechanical ventila-
tion, remains the leading complication with paramount
clinical importance in comatose OHCA survivors.Study limitations
Several limitations of our study should be acknowledged.
First, despite the fact that the MTH and control groups
were relatively well-matched, the non-randomized and
retrospective design of our study may result in overesti-
mation of benefits related to MTH therapy. Second, the
limited sample sizes of our study preclude comprehensive
sub-group analyses and substantially reduce the possibility
to perform complex multivariate analyses. Third, the stable
care assumption, inherent to the choice of historical con-
trols, should be mentioned as an another important limita-
tion of our study. Fourth, our observation is restricted to
the in-hospital period. Although neurologic status at hos-
pital discharge and all-cause in-hospital mortality constitute
common endpoints in MTH studies, prolongation of the
follow-up would definitely increase the value of our find-
ings. Fifth, differences in the underlying cause of OHCA
between patients treated with and without MTH as well as
in door-to-balloon times, namely preponderance of patients
with ST-segment elevation myocardial infarction and non-
coronary OHCA aetiology in the MTH group and non-ST
-segment elevation ACS subjects in the control group, to-
gether with shorter door-to-balloon time in the former,
might have influenced the results. Sixth, the relatively long
time needed to achieve the state of MTH in our study, des-
pite the implementation of the endovascular cooling sys-
tem, might possibly attenuate clinical advantages derived
from MTH therapy. It was caused by the initiation of
endovascular cooling in Cardiac Intensive Care Sub-unit
after the completion of coronary interventional manage-
ment. Additionally, none of the study participants was be-
ing cooled before hospital admission and no ice packs were
attached to the patients’ chest during coronary angiography
and PCI to avoid adverse effects on the quality of images.
Seventh, there was a statistically non-significant discrepancy
concerning the use of IABP support in patients with cardio-
genic shock between the MTH and control groups. It was
driven by the recent critical appraisal of IABP treatment in
this setting and a gradual decrease in IABP utilization in
routine practice due to the lack of proven clinical benefits
associated with this therapy [50].
Conclusions
Our study indicates that a regional system of care for
OHCA survivors may be successfully implemented based
on an ACS network, leading to an improvement in neuro-
logical status and to a reduction of in-hospital mortality in
patients treated with MTH, without any excess of compli-
cations. However, our findings should be verified in large,
prospective trials.
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